Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Are you Dr. Raghav?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Kanwal Raghav, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Arizona.
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
- Albert Einstein Healthcare NetworkResidency, Internal Medicine, 2006 - 2009
- University of Arkansas For Medical Sciences College of MedicineClass of 2005
- Delhi University College of Medical SciencesClass of 2004
Certifications & Licensure
- FL State Medical License 2021 - Present
- AZ State Medical License 2024 - 2026
- OK State Medical License 2020 - 2026
- OK State Medical License 2020 - 2026
- TN State Medical License 2024 - 2026
- AL State Medical License 2024 - 2025
- GA State Medical License 2024 - 2025
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Publications & Presentations
PubMed
- BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy.Vinay K Pattalachinti, Emaan Haque, Mahmoud Yousef, Abdelrahman Yousef, Saikat Chowdhury
NPJ Precision Oncology. 2025-02-05 - The Landscape of ctDNA in Appendiceal Adenocarcinoma.Michael G White, Mohammad A Zeineddine, Eleanor A Fallon, Fadl A Zeineddine, Julia Dansby
Clinical Cancer Research. 2025-02-03 - 1 citationsMOUNTAINEER-03 phase III study design: first-line mFOLFOX6 + tucatinib + trastuzumab for HER2+ metastatic colorectal cancer.John H Strickler, Tanios Bekaii-Saab, Andrea Cercek, Volker Heinemann, Yoshiaki Nakamura
Future Oncology. 2025-02-01
Press Mentions
- New Anti-HER2 Therapy Shows Promise as a Less Toxic Option for HER2+ Colorectal CancerJanuary 29th, 2025
- MD Anderson Research Highlights for August 21, 2024August 21st, 2024
- Confirmed Antitumor Activity with T-dXd for HER2-Positive Metastatic CRCAugust 16th, 2024
- Join now to see all